YONKERS, N.Y., Feb. 25 /PRNewswire-FirstCall/ -- Advanced Viral Research
Corp. (OTC Bulletin Board: ADVR) today announced that it was issued a United
States patent (No. 6,696,422) for the treatment of HIV infections with AVR118
as a combination therapy with other HIV drugs.
The Centers for Disease Control and Prevention (CDC) estimates that
850,000 to 950,000 United States residents are living with HIV infection,
one-quarter of whom are unaware of their infection. Over 40,000 new patients
are diagnosed with HIV infections each year in the United States -- about 70
percent among men and 30 percent among women. Of these newly infected people,
half are younger than 25 years of age.
"The issuance of this patent allows us to increase our intellectual
property protection in an important therapeutic area," said Dr. Elma Hawkins,
President and CEO of Advanced Viral Research Corp. "We previously announced
that China granted the Company a similar patent for AVR118 in the treatment of
HIV infections."
ADVR's AVR118 represents a biopolymer that possesses novel immunomodulator
activity. This peptide-nucleic acid, which to date has shown a very favorable
safety profile, appears to stimulate the proinflammatory responses required to
combat viral infections such as HIV and human papillomavirus and to dampen
aberrant autoimmune-type inflammatory responses, such as occur in patients
with rheumatoid arthritis. AVR118 is in clinical trials in Israel for the
treatment of cachexia (body wasting) in patients with AIDS.
For further information regarding Advanced Viral Research Corp., please
visit our website at http://www.adviral.com. Advanced Viral Research Corp., based in
Yonkers, New York, is a biopharmaceutical firm dedicated to improving
patients' lives by researching, developing and bringing to market new and
effective therapies for viral and other diseases.
Note: This news release contains forward-looking statements that involve
risks associated with clinical development, regulatory approvals, including
application to the FDA, product commercialization and other risks described
from time to time in the SEC reports filed by the Company. AVR118 (previously
known as Product R) is not approved by the U.S. Food and Drug Administration
or any comparable agencies of any other countries. There is no assurance that
the Company will be able to secure the financing necessary to continue and/or
complete the clinical trials of AVR118 or satisfy certain other conditions
relating to clinical trials including obtaining adequate insurance on terms
acceptable to the Company or that if completed, clinical trials performed
outside the United States will assist the Company in obtaining FDA or other
regulatory approval. . The Company undertakes no obligation to update or
revise the information contained in this announcement whether as a result of
new information, future events or circumstances or otherwise.
Contact: Ronnie Welch or
Kelly Cinelli
CWR & Partners
508/222-4802
SOURCE Advanced Viral Research Corp.
 back to top
Related links:
http://www.adviral.com
Company News On-Call:
http://www.prnewswire.com/comp/903002.html
CONTACT:
Ronnie Welch or Kelly Cinelli, both of CWR &
Partners, for Advanced Viral Research Corp., +1-508-222-4802
|
